CY1122432T1 - Θεραπεια καρκινου χρησιμοποιωντας ανταγωνιστη υποδοχεα αυξητικου παραγοντα ινσουλινης-τυπου (igf) σε συνδυασμο με εξεμεστανη και εβερολιμη - Google Patents
Θεραπεια καρκινου χρησιμοποιωντας ανταγωνιστη υποδοχεα αυξητικου παραγοντα ινσουλινης-τυπου (igf) σε συνδυασμο με εξεμεστανη και εβερολιμηInfo
- Publication number
- CY1122432T1 CY1122432T1 CY20191101287T CY191101287T CY1122432T1 CY 1122432 T1 CY1122432 T1 CY 1122432T1 CY 20191101287 T CY20191101287 T CY 20191101287T CY 191101287 T CY191101287 T CY 191101287T CY 1122432 T1 CY1122432 T1 CY 1122432T1
- Authority
- CY
- Cyprus
- Prior art keywords
- exemestane
- igf
- insulin
- treatment
- combination
- Prior art date
Links
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 title abstract 2
- 229960000255 exemestane Drugs 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000013275 Somatomedins Human genes 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 1
- 229960005167 everolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14152416 | 2014-01-24 | ||
| EP15703743.3A EP3096792B1 (en) | 2014-01-24 | 2015-01-23 | Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus |
| PCT/EP2015/051308 WO2015110560A1 (en) | 2014-01-24 | 2015-01-23 | Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122432T1 true CY1122432T1 (el) | 2021-01-27 |
Family
ID=49999770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101287T CY1122432T1 (el) | 2014-01-24 | 2019-12-05 | Θεραπεια καρκινου χρησιμοποιωντας ανταγωνιστη υποδοχεα αυξητικου παραγοντα ινσουλινης-τυπου (igf) σε συνδυασμο με εξεμεστανη και εβερολιμη |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150209426A1 (enExample) |
| EP (1) | EP3096792B1 (enExample) |
| JP (1) | JP6712226B2 (enExample) |
| CY (1) | CY1122432T1 (enExample) |
| DK (1) | DK3096792T3 (enExample) |
| ES (1) | ES2755933T3 (enExample) |
| HR (1) | HRP20192260T1 (enExample) |
| HU (1) | HUE047614T2 (enExample) |
| LT (1) | LT3096792T (enExample) |
| PL (1) | PL3096792T3 (enExample) |
| PT (1) | PT3096792T (enExample) |
| RS (1) | RS59649B1 (enExample) |
| SI (1) | SI3096792T1 (enExample) |
| WO (1) | WO2015110560A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2376116T1 (sl) | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US20200239559A1 (en) * | 2017-09-29 | 2020-07-30 | Boehringer Ingelheim International Gmbh | Anti igf, anti pd-1, anti-cancer combination therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| SI2376116T1 (sl) * | 2008-12-12 | 2016-03-31 | Boehringer Ingelheim International Gmbh | Anti-IGF protitelesa |
| WO2013169611A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
-
2015
- 2015-01-23 HR HRP20192260TT patent/HRP20192260T1/hr unknown
- 2015-01-23 SI SI201531004T patent/SI3096792T1/sl unknown
- 2015-01-23 JP JP2016548192A patent/JP6712226B2/ja not_active Expired - Fee Related
- 2015-01-23 LT LTEP15703743.3T patent/LT3096792T/lt unknown
- 2015-01-23 DK DK15703743T patent/DK3096792T3/da active
- 2015-01-23 EP EP15703743.3A patent/EP3096792B1/en active Active
- 2015-01-23 RS RS20191566A patent/RS59649B1/sr unknown
- 2015-01-23 HU HUE15703743A patent/HUE047614T2/hu unknown
- 2015-01-23 PT PT157037433T patent/PT3096792T/pt unknown
- 2015-01-23 US US14/603,503 patent/US20150209426A1/en not_active Abandoned
- 2015-01-23 PL PL15703743T patent/PL3096792T3/pl unknown
- 2015-01-23 WO PCT/EP2015/051308 patent/WO2015110560A1/en not_active Ceased
- 2015-01-23 ES ES15703743T patent/ES2755933T3/es active Active
-
2019
- 2019-12-05 CY CY20191101287T patent/CY1122432T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE047614T2 (hu) | 2020-04-28 |
| LT3096792T (lt) | 2019-12-27 |
| DK3096792T3 (da) | 2019-12-09 |
| SI3096792T1 (sl) | 2020-01-31 |
| WO2015110560A1 (en) | 2015-07-30 |
| HRP20192260T1 (hr) | 2020-03-06 |
| JP2017505311A (ja) | 2017-02-16 |
| EP3096792B1 (en) | 2019-09-25 |
| ES2755933T3 (es) | 2020-04-24 |
| EP3096792A1 (en) | 2016-11-30 |
| US20150209426A1 (en) | 2015-07-30 |
| PT3096792T (pt) | 2020-01-08 |
| JP6712226B2 (ja) | 2020-06-17 |
| RS59649B1 (sr) | 2020-01-31 |
| PL3096792T3 (pl) | 2020-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| NI201700019A (es) | Anticuerpos anti tigit | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| MX2017005553A (es) | Terapia de combinacion para cancer. | |
| ZA201902320B (en) | 17alpha,21-diesters of cortexolone for use in the treatment of tumors | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| GEP201706612B (en) | Methods for the treatment of breast cancer | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| ZA202503350B (en) | Semaglutide in medical therapy | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| AU350280S (en) | Apparatus for skin treatment | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| CR20140400A (es) | Terapia combinada para el tratamiento del cancer de ovario | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
| CY1122432T1 (el) | Θεραπεια καρκινου χρησιμοποιωντας ανταγωνιστη υποδοχεα αυξητικου παραγοντα ινσουλινης-τυπου (igf) σε συνδυασμο με εξεμεστανη και εβερολιμη | |
| CY1123284T1 (el) | Συνθεση που περιλαμβανει υδροκορτιζονη | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина |